News and Insights from Our Multidisciplinary Team of Experts
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...
Genomenon’s genomic landscapes enhance Flagship’s biomarker services and companion diagnostic development solutions
Broomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced a strategic partnership…
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...
EVENTS
Are you attending the 2024 ASGCT Annual Meeting?With field-leading keynotes, 200+ scientific sessions, over 7,000 researchers in attendance, and an expanded exhibit hall, the 27th American Society of Gene and Cell Therapy Annual Meeting is the nexus for gene and cell...
Meet with us at the AACR Annual Meeting 2024 to learn about our spatial biology solutions. Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the...
Meet with us at the Spatial Biology for Immuno-Oncology Summit.The Spatial Biology for Immuno-Oncology Summit is back for its second year, and Flagship Biosciences is a Program Partner for the event. Join us January 23-25 in San Diego where key industry leaders will...